We are devoted to strengthening emerging pharmaceutical markets. To this end, we commit to upholding essential principles in all of our dealings with clients. Our Client Charter is our promise to you that ...
Our Quality Edge is how we blend Empathy, Reliability and Responsiveness to deliver exceptional service to all our clients.
We Partner with Clients to execute Outcomes Research in emerging markets.
We develop results-driven market access solutions for clients in emerging markets.
We are devoted to strengthening emerging pharmaceutical markets.
Market Access Solutions
Innovative Access Strategies
Our Quality Edge
South Africa: unions cautious about consolidation of medical schemes for public servants in preparation for NHI phrmaccess.com/x/up pic.twitter.com/YqQ8246jJw
Yesterday from Carapinha & Company's Twitter
USA: Pharma innovation is stuck in an “old 1980s payment model” phrmaccess.com/x/ut pic.twitter.com/VUcyWXlDvP
Will big pharma exit the biosimilar market when margins start dropping? phrmaccess.com/x/uk pic.twitter.com/hXX7fMG020
About 3 days ago from Carapinha & Company's Twitter
EU Parliament puts a brake on a simplified EU-wide HTA system phrmaccess.com/x/un pic.twitter.com/KXqMMSaJAr
Emirates Diabetes Society recommends improved awareness and more educational programmes phrmaccess.com/x/ue pic.twitter.com/zQMz8TNGce
About 5 days ago from Carapinha & Company's Twitter
South Africa: merging of public servant medical schemes meets opposition in preparation for NHI phrmaccess.com/x/uf pic.twitter.com/FBC9afDhvL
The mid-term elections in the US may usher new drug-pricing reforms phrmaccess.com/x/u7 pic.twitter.com/r8LJXqrbLo
Last week from Carapinha & Company's Twitter
Innovative approaches needed to overcome challenges with improving access to personalised medicines phrmaccess.com/x/u9 pic.twitter.com/qNdsRPZcZX
Leverage, Transparency, and Competition suggested goals for lowering drug prices in the U.S phrmaccess.com/x/uc pic.twitter.com/JbULoN1f5Y
Did you know, since 2007 we have built stronger pharmaceutical markets. Don't be left behind, see our infographic on how we get business done! carapinha.com/link/infograph… pic.twitter.com/vPoFbHq19I
Novartis reduces it’s drug development program by 20% to 340, amid other comparable R&D consolidations phrmaccess.com/x/u1 pic.twitter.com/98In0NchEq
South Africa: Democratic Alliance proposes an alternative “Our Health Plan” amidst failing NHI pilot projects phrmaccess.com/x/u4 pic.twitter.com/8GhwIhDJyC
South Africa: Health Minister explains chronic underspending in various areas including NHI phrmaccess.com/x/u5 pic.twitter.com/d2Ea5YWfdv
Cerevel Therapeutics launched: a JV between Bain Capital and Pfizer focused on CNS phrmaccess.com/x/tv pic.twitter.com/VUrafBLWcY
IPHA in Ireland finds it challenging establishing partnerships with key stakeholders and authorities phrmaccess.com/x/ty pic.twitter.com/CFcfR7e1Jv